Skip to main content

Drug Abuse

3
Pipeline Programs
5
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
2 programs
1
1
PrometaPhase 2/31 trial
THCPhase 1
Active Trials
NCT00260481Completed120Est. Jun 2008
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
TC-5214Phase 11 trial
Active Trials
NCT01500018Withdrawn0Est. Apr 2012
Teva
TevaIsrael - Petach Tikva
1 program
45-mg hydrocodone bitartrate extended-release tabletPHASE_11 trial
Active Trials
NCT01596673Completed100Est. May 2012
Kyowa Hakko Kirin
Kyowa Hakko KirinCA - La Jolla
1 program
IstradefyllinePHASE_11 trial
Active Trials
NCT02609477Completed42Est. Jul 2016

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Angeles TherapeuticsPrometa
Kyowa Hakko KirinIstradefylline
Teva45-mg hydrocodone bitartrate extended-release tablet
AstraZenecaTC-5214

Clinical Trials (4)

Total enrollment: 262 patients across 4 trials

NCT00260481Angeles TherapeuticsPrometa

Prometa Pharmacotherapy for Methamphetamine Dependence

Start: Jan 2006Est. completion: Jun 2008120 patients
Phase 2/3Completed
NCT02609477Kyowa Hakko KirinIstradefylline

A Study to Evaluate Abuse Potential of Istradefylline

Start: Jan 2016Est. completion: Jul 201642 patients
Phase 1Completed
NCT01596673Teva45-mg hydrocodone bitartrate extended-release tablet

A Study to Assess the Abuse Potential of Hydrocodone Extended-Release Tablet in Recreational Opioid Users

Start: Mar 2012Est. completion: May 2012100 patients
Phase 1Completed
NCT01500018AstraZenecaTC-5214

Study in Healthy Recreational Polydrug Users to Measure the Abuse Potential of TC-5214

Start: Jan 2012Est. completion: Apr 20120
Phase 1Withdrawn

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.